The US FDA has broadened the indication of Vanos, a Class I corticosteroid launched by Medicis in April 2005 and originally indicated for the treatment of plaque-type psoriasis. Vanos is now indicated as a primary therapy for all inflammatory and pruritic skin conditions in patients 12 years of age or older which are responsive to corticosteroids. Such conditions include eczema and poison ivy, which occur commonly.

The unique formulation of Vanos provides doctors and patients with the convenience of a super high potency vehicle in the form of a cream for once or twice daily application in psoriasis and once daily in the other indicated conditions. Vanos is patent protected until 2021.

Vanos is available by prescription in a 30-gram size and a 60-gram size.

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine.